• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cross-sectional analysis of retrospective case series of hospitalisations for gastropathy caused by non-steroidal anti-inflammatory treatment: risk factors and gastroprotection use.非甾体抗炎治疗所致胃病住院病例系列的横断面回顾性分析:危险因素及胃保护措施的使用情况
Eur J Hosp Pharm. 2017 Nov;24(6):355-360. doi: 10.1136/ejhpharm-2016-001087. Epub 2016 Nov 7.
2
Risk factors associated with NSAID-induced upper gastrointestinal bleeding resulting in hospital admissions: A cross-sectional, retrospective, case series analysis in valencia, spain.与导致住院的非甾体抗炎药引起的上消化道出血相关的危险因素:西班牙巴伦西亚的一项横断面、回顾性病例系列分析
Curr Ther Res Clin Exp. 2007 Mar;68(2):107-19. doi: 10.1016/j.curtheres.2007.03.003.
3
Complications of nonsteroidal antiiflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center.非甾体抗炎药所致胃病的并发症及胃黏膜保护的应用:一家三级医疗保健中心的经验
J Rheumatol. 1999 Jul;26(7):1557-63.
4
Pharmacist intervention reduces gastropathy risk in patients using NSAIDs.药剂师干预可降低使用非甾体抗炎药患者的胃病风险。
Pharm World Sci. 2008 Dec;30(6):947-54. doi: 10.1007/s11096-008-9258-8. Epub 2008 Oct 19.
5
Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies.老年患者使用非甾体抗炎药时胃保护剂的联合应用及其疗效:观察性研究的系统评价。
Clin Gastroenterol Hepatol. 2013 Oct;11(10):1259-1269.e10. doi: 10.1016/j.cgh.2013.05.034. Epub 2013 Jun 21.
6
From peptic ulcer disease to NSAID gastropathy. An evolving nosology.从消化性溃疡病到非甾体抗炎药相关性胃病。一种不断演变的疾病分类学。
Drugs Aging. 1995 May;6(5):358-67. doi: 10.2165/00002512-199506050-00003.
7
Gastroprotective agents for the prevention of NSAID-induced gastropathy.用于预防非甾体抗炎药引起的胃病的胃保护剂。
Curr Pharm Des. 1998 Feb;4(1):17-36.
8
Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.非甾体抗炎药(NSAIDs)、环氧化酶-2选择性抑制剂(coxibs)与胃肠道损害:临床试验及临床实践综述
BMC Musculoskelet Disord. 2006 Oct 20;7:79. doi: 10.1186/1471-2474-7-79.
9
Utilization of gastroprotective strategies for nonsteroidal anti-inflammatory drug-induced gastrointestinal events in a major teaching hospital.在一家大型教学医院中针对非甾体抗炎药引起的胃肠道事件采用胃保护策略。
Ther Clin Risk Manag. 2016 Nov 10;12:1649-1657. doi: 10.2147/TCRM.S119722. eCollection 2016.
10
Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis.类风湿关节炎患者临床明显溃疡及其并发症的发生率。
Ann Rheum Dis. 2001 May;60(5):443-7. doi: 10.1136/ard.60.5.443.

引用本文的文献

1
Non-steroidal anti-inflammatory drugs and gastroprotection in primary health care users.基层医疗保健使用者中的非甾体抗炎药与胃保护
Med Pharm Rep. 2020 Jul;93(3):246-252. doi: 10.15386/mpr-1533. Epub 2020 Jul 22.
2
Use of Non-Steroidal Anti-Inflammatory Drugs and Associated Gastroprotection in a Cohort of Workers.非甾体抗炎药的使用及相关胃保护在工人队列中的应用。
Int J Environ Res Public Health. 2018 Aug 24;15(9):1836. doi: 10.3390/ijerph15091836.

本文引用的文献

1
[NSAID and gastrointestinal risk].[非甾体抗炎药与胃肠道风险]
Aten Primaria. 2016 Feb;48(2):73-6. doi: 10.1016/j.aprim.2015.04.008.
2
Risk factors associated with NSAID-induced upper gastrointestinal bleeding resulting in hospital admissions: A cross-sectional, retrospective, case series analysis in valencia, spain.与导致住院的非甾体抗炎药引起的上消化道出血相关的危险因素:西班牙巴伦西亚的一项横断面、回顾性病例系列分析
Curr Ther Res Clin Exp. 2007 Mar;68(2):107-19. doi: 10.1016/j.curtheres.2007.03.003.
3
[Gastrointestinal bleeding associated with NSAIDs, antiplatelet therapy and anticoagulant agent].[非甾体抗炎药、抗血小板治疗及抗凝剂相关的消化道出血]
Gastroenterol Hepatol. 2012 Sep;35 Suppl 1:35-42. doi: 10.1016/S0210-5705(12)70032-8.
4
Long-term use of aspirin and the risk of gastrointestinal bleeding.长期使用阿司匹林与胃肠道出血风险。
Am J Med. 2011 May;124(5):426-33. doi: 10.1016/j.amjmed.2010.12.022.
5
Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications.低剂量乙酰水杨酸单用和与氯吡格雷及其他药物合用对上消化道出血的风险。
Circulation. 2011 Mar 15;123(10):1108-15. doi: 10.1161/CIRCULATIONAHA.110.973008. Epub 2011 Feb 28.
6
Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States.高危行经皮冠状动脉介入治疗患者胃保护剂的未充分利用:西班牙与美国比较。
Aliment Pharmacol Ther. 2010 Sep;32(5):689-95. doi: 10.1111/j.1365-2036.2010.04393.x.
7
[Prescribing non-steroidal antiinflammatory drugs and gastrointestinal protection in primary care].[基层医疗中开具非甾体抗炎药与胃肠道保护]
Aten Primaria. 2008 Nov;40(11):559-64. doi: 10.1157/13128569.
8
Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.与选择性环氧化酶-2抑制剂、传统非阿司匹林非甾体抗炎药、阿司匹林及其联合用药相关的上消化道溃疡出血风险
Gut. 2006 Dec;55(12):1731-8. doi: 10.1136/gut.2005.080754. Epub 2006 May 10.
9
[Trends of non-steroidal anti-inflammatory drugs use in Spain, 1990 through 2003].[1990年至2003年西班牙非甾体抗炎药的使用趋势]
Aten Primaria. 2005 Nov;36(8):424-33. doi: 10.1157/13081056.
10
Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents.与非甾体抗炎药使用相关的上消化道出血:新型药物与传统药物对比
Drug Saf. 2004;27(6):411-20. doi: 10.2165/00002018-200427060-00005.

非甾体抗炎治疗所致胃病住院病例系列的横断面回顾性分析:危险因素及胃保护措施的使用情况

Cross-sectional analysis of retrospective case series of hospitalisations for gastropathy caused by non-steroidal anti-inflammatory treatment: risk factors and gastroprotection use.

作者信息

Marco Garbayo José Luis, Koninckx Cañada Manuel, Pérez Castelló Isabel, Faus Soler María Teresa, Fuster Torres Rosa, Moncho Escrivà Mar

机构信息

Department of Hospital Pharmacy, Francesc de Borja Hospital of Gandia, Valencia, Spain.

Department of Clinical Documentation and Admission, Francesc de Borja Hospital of Gandia, Valencia, Spain.

出版信息

Eur J Hosp Pharm. 2017 Nov;24(6):355-360. doi: 10.1136/ejhpharm-2016-001087. Epub 2016 Nov 7.

DOI:10.1136/ejhpharm-2016-001087
PMID:31156971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6451491/
Abstract

OBJECTIVES

To analyse the risk factors of gastropathy caused by using non-steroidal anti-inflammatory drugs (NSAIDs) in detected hospital admissions and to analyse the use of gastroprotective treatment concerning these risk factors.

METHODS

A retrospective observational study was carried out in the framework of an integral risk management plan of drugs and proactive pharmacovigilance of hospital admissions for NSAID-induced gastropathy occurring between 2011 and 2015. Cases were identified after reviewing the ICD-9 codes related to NSAID-induced gastropathy in hospital discharge reports. Various biometric, clinical and pharmacotherapeutic variables of each patient were registered. The gastroprotective criteria set out in the therapeutic decision algorithm of the Valencian Health System were followed.

RESULTS

62 hospital admissions for NSAID-induced gastropathy were detected. The mean length of stay was 5.3±3.8 days. Ibuprofen was the most prevalent NSAID (28 cases, 45.2%). 24 cases (38.7%) took NSAIDs in the week before hospitalisation. The prevalence of relevant risk factors for gastropathy were age >60 years (37 cases, 59.7%), concomitant medication (24 cases, 38.7%) and a history of peptic ulcer (9 cases, 14.5%). 41 patients (66.1%) met gastroprotective major criteria, 18 of whom (43.9%) were using a proton pump inhibitor following a prevention plan.

CONCLUSIONS

In this study all relevant gastroprotective criteria were associated with the use of gastroprotection in detected hospital admissions for NSAID-induced gastropathy. However, a lack of gastroprotection was observed in a large number of detected cases with the criteria to use it. The feedback of our results to health area agents can serve to reinforce the safe use of NSAIDs.

摘要

目的

分析在已确诊的住院病例中使用非甾体抗炎药(NSAIDs)导致胃病的危险因素,并分析针对这些危险因素的胃保护治疗的使用情况。

方法

在2011年至2015年期间发生的NSAID引起的胃病住院患者的药物综合风险管理计划和主动药物警戒框架内进行了一项回顾性观察研究。通过审查医院出院报告中与NSAID引起的胃病相关的ICD-9编码来确定病例。记录了每位患者的各种生物统计学、临床和药物治疗变量。遵循瓦伦西亚卫生系统治疗决策算法中规定的胃保护标准。

结果

检测到62例因NSAID引起的胃病住院病例。平均住院时间为5.3±3.8天。布洛芬是最常见的NSAID(28例,45.2%)。24例(38.7%)在住院前一周服用了NSAIDs。胃病相关危险因素的患病率为年龄>60岁(37例,59.7%)、合并用药(24例,38.7%)和消化性溃疡病史(9例,14.5%)。41例患者(66.1%)符合胃保护主要标准,其中18例(43.9%)按照预防计划使用质子泵抑制剂。

结论

在本研究中,所有相关的胃保护标准都与在已确诊的NSAID引起的胃病住院病例中使用胃保护措施相关。然而,在大量符合使用标准的已确诊病例中观察到缺乏胃保护措施的情况。将我们的结果反馈给卫生领域的相关人员有助于加强NSAIDs的安全使用。